Skip to main content
Quest Diagnostics

Pioglitazone Improves Apolipoprotein A1-Associated Proteomic Composition More Than Weight Loss in Insulin Resistance

AHA Vascular Discovery 2024

Chicago IL, May 15-18 2024

Poster presentation: Pioglitazone Improves Apolipoprotein A1-Associated Proteomic Composition More Than Weight Loss in Insulin Resistance

Authors: Parsa S, Collier TS, McPhaul MJ,  Mellander O, Knowles JW, Rohatgi A, Abbasi F

Specialty: Endocrinology, Cardiology

Related content

Publication
Weight Loss Before Conception: Effects on Atherogenic Apolipoprotein Lipid Particles and Endothelial Function During Pregnancy
Audio Podcast
Instant Insights: Apolipoprotein B
Conference Presentation
The LS-IM Score And Its Relation To Direct Measurements Of Insulin Resistance
Audio Podcast
Actions From Insight: GLP-1 Receptor Antagonists and Building Healthy Habits
Publication
Insulin Resistance Probability Score and Incident Cardiovascular Disease
On-Demand Webinar
Cardiovascular Clinical Conversations: Understanding the Function of HDL—Beyond Its Levels

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.